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The authors reply: Okamoto suggests that de-
termining whether there are differences in titers 
of autoantibodies and epitope specificity in 
Goodpasture’s disease on the basis of lung in-
volvement might be beneficial for understanding 
the mechanism of this disease. In one study, pa-
tients with Goodpasture’s disease who had posi-
tive results for both ANCA and anti-GBM anti-
bodies had a poor prognosis when they presented 
with severe renal failure.1 Other studies reported 
no difference between patients with ANCA and 
those without ANCA with respect to the NC1-
antigen specificity of anti-GBM antibodies.2 In 
our study, 12 of 46 patients had lung hemor-
rhage. However, there was no difference in auto-
antibody titers between patients with hemorrhage 
and those without hemorrhage. Furthermore, de-
spite the earlier suggestion that the prognosis for 
double-positive patients may be dependent on 
both populations of antibodies,3 we did not find 
any difference between patients with ANCA and 
those without ANCA in titers of circulating anti-
α3NC1 or anti-α5NC1 autoantibodies. Our analy-
sis of antibody epitopes indicates that conforma-
tional changes occur in collagen IV α345NC1 
with no difference in the presence of concomi-
tant ANCA. Thus, any influence of ANCA on the 
severity of lesions among patients with Goodpas-
ture’s disease does not appear to be mediated by 
changes in epitope conformation.
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Valproic Acid Use in Pregnancy and Congenital Malformations
To the Editor: In their article describing val-
proic acid monotherapy in pregnancy and major 
congenital malformations (June 10 issue),1 Jen-
tink and colleagues concluded by recommending 
that the use of valproic acid be avoided, if possi-
ble, in women of childbearing potential. However, 
this study did not assess the effect of the dose of 
valproic acid on the risk of birth defects. In many 
patients with primary generalized epilepsy, the 
condition is well controlled with the use of low 
doses of valproic acid (<1000 mg). Among preg-
nant women in the Australian Pregnancy Register, 
the risk of teratogenic effects was not significant-
ly higher with valproic acid than with alternative 
antiepileptic drugs, and seizure control was better 
in patients treated with valproic acid than in those 
treated with lamotrigine or carbamazepine, in any 
trimester of pregnancy.2 Seizures endanger the 
mother as well as the fetus. We believe that a 
more appropriate conclusion is that high doses 
of valproic acid should not be used as a first-
choice drug in women of childbearing potential.
Frank Vajda, M.D.
University of Melbourne 
Parkville, VIC, Australia 
vajda@netspace.net.au
Terence O’Brien, M.D.
Royal Melbourne Hospital 
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The Authors and a Colleague Reply: As we 
mentioned in our article, we did not have infor-
mation on doses of valproic acid; therefore we 
cannot draw any conclusion about doses of val-
proic acid and the risk of congenital malforma-
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tions. We think that caution should be exercised 
when conclusions are drawn about doses of val-
proic acid given during pregnancy. The study by 
Vajda and colleagues had a relatively small sam-
ple (113 pregnancies involving in utero exposure 
to valproic acid monotherapy) and did not include 
information on specific malformations.1 In a 
study including 715 pregnancies involving expo-
sure to valproic acid monotherapy, the mean ma-
ternal daily dose of valproic acid did not differ 
significantly between the offspring without mal-
formations and those with malformations.2 A 
higher prevalence of congenital malformations 
has also been noted in association with lower 
doses of valproic acid, as compared with other 
antiepileptic drugs.1,2 Case–control studies in-
cluding large numbers of pregnancies in which 
there is exposure to a range of doses of valproic 
acid and including information about specific 
malformations could help inform whether a low 
dose of valproic acid is safe in terms of the risk 
of congenital malformation.3
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Early Alzheimer’s Disease
To the Editor: The example of a 72-year-old 
man with memory problems in the article by 
Mayeux (June 10 issue)1 suggests both the com-
plexities of diagnosing Alzheimer’s disease and 
the idea that older patients are now likely to be 
employed. As the world’s population ages, these 
are issues with which all physicians will need to 
become familiar. Many of the appropriate inter-
ventions are nonpharmacologic; Mayeux address-
es this subject comprehensively with respect to 
driving, but he does not mention other interven-
tions. Our own practice is to advise all patients 
presenting with memory problems and their 
families to consider a durable power of attorney. 
Most states have legislated for a specific legal 
representation, the health care proxy who may 
make decisions should the patient become inca-
pacitated.2 Advance care directives are an alterna-
tive, but ethical concerns remain with respect to 
their applicability.3 The use of health care proxies 
sidesteps some of these issues and should be in-
cluded in the advice offered to these patients.
Lisa Lavelle, M.B. 
David J. Robinson, M.B. 
Diarmuid O’Shea, M.D.
St. Vincent’s Hospital  
Dublin, Ireland 
davidjrobinson@iol.ie
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To the Editor: Although many of the diagnostic 
and practical dilemmas of early Alzheimer’s dis-
ease are covered in the Clinical Practice article by 
Mayeux, an outstanding area of concern is the 
effect of early Alzheimer’s disease on occupa-
tion. In societies with healthier older people and 
abolition of mandatory retirement,1 clinicians 
who care for patients with dementia are present-
ed increasingly with patients (such as the invest-
ment manager in the case vignette in the article) 
whose jobs demand high levels of performance.
Discussion with the patient, encouraging him 
or her to talk about ongoing work with occupa-
tional health services or the employer, is an initial 
pragmatic step. However, there is an urgent need 
for joint development of solutions by occupa-
tional health specialists, geriatricians, and neu-
rologists regarding continued working and early 
dementia; these solutions should preserve inde-
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